Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Total Current Liabilities came in at $963.7 million in Q2 2026, up 2.27% YoY from $942.3 million in Q2 2025, and up 3.72% on a QoQ basis from $929.1 million in Q1 2026.
Fortrea Holdings (FTRE) Total Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Total Current Liabilities data on file, last reported at $963.7 million in Q2 2026.
- Quarterly Total Current Liabilities rose 2.27% year-over-year to $963.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $963.7 million (up 2.27% YoY) and the FY2025 annual result came in at $913.3 million, down 3.81% from the prior year.
- Total Current Liabilities climbed to $963.7 million in Q2 2026, from $929.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $999.1 million in Q1 2025 to a low of $699.0 million in Q4 2022.
- A 5-year average of $855.6 million and a median of $865.8 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities climbed 25.81% — and 2026, when it slipped 7.01%.
- Tracing FTRE's Total Current Liabilities over 5 years: stood at $699.0 million in 2022, then increased by 11.36% to $778.4 million in 2023, then grew by 21.98% to $949.5 million in 2024, then retreated by 3.81% to $913.3 million in 2025, then increased by 5.52% to $963.7 million in 2026.
- The last three Total Current Liabilities figures came in at $963.7 million (Q2 2026), $929.1 million (Q1 2026), and $913.3 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 963.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 963.70 Mn |
| Mar 31, 2026 | 929.10 Mn |
| Dec 31, 2025 | 913.30 Mn |
| Sep 30, 2025 | 914.40 Mn |
| Jun 30, 2025 | 942.30 Mn |
| Mar 31, 2025 | 999.10 Mn |
| Dec 31, 2024 | 949.50 Mn |
| Sep 30, 2024 | 795.80 Mn |
| Jun 30, 2024 | 749.00 Mn |
| Mar 31, 2024 | 818.30 Mn |
| Dec 31, 2023 | 778.40 Mn |
| Sep 30, 2023 | 774.60 Mn |
| Jun 30, 2023 | 752.10 Mn |
| Dec 31, 2022 | 699.00 Mn |